Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 11Myelodysplastic Syndromes 3Leukemia 3Sarcoma, Myeloid 1Recurrence 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1

Interventions

Cytarabine 21Cyclophosphamide 21fludarabine 18Whole-Body Irradiation 18venetoclax 15fludarabine phosphate 15Specimen Handling 15Methotrexate 15Mycophenolic Acid 13Vincristine 9Biopsy 9merphos 8Granulocyte Colony-Stimulating Factor 8Filgrastim 8Dexamethasone 8calaspargase pegol 7blinatumomab 7Stem Cell Transplantation 7Peripheral Blood Stem Cell Transplantation 7Hydrocortisone 7Busulfan 7Azacitidine 7revumenib 6Tacrolimus 6Melphalan 6Idarubicin 6Daunorubicin 6Asparaginase 6X-Rays 5Thiotepa 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Biphenotypic, Acute × quizartinib × 1 year × Clear all
NCT04047641 2025-12-17

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡